42 citations
,
April 2012 in “Seminars in Oncology” This review discusses the skin side effects associated with targeted cancer therapies and reports no new clinical results; it emphasizes the need for empirical management based on expert opinion.
45 citations
,
January 2007 in “Journal of Clinical Oncology” This case report identifies hand-foot and stump syndrome as a potential side effect of sorafenib therapy in a 47-year-old man with a leg amputation.
11 citations
,
December 2013 in “Clinical and Experimental Dermatology” This article reviews the use of sorafenib, a multikinase inhibitor, for treating certain carcinomas, noting that cutaneous toxicity during treatment may indicate successful antitumor activity; however, it reports no new clinical results.
508 citations
,
June 2009 in “Current drug metabolism” This review details the skin and hematological toxicities of tyrosine kinase inhibitors like erlotinib, gefitinib, and imatinib, and highlights ongoing concerns about cardiac toxicity, reporting no new clinical findings.
March 2014 in “Journal of The American Academy of Dermatology” Reflectance confocal microscopy can noninvasively diagnose onychomatricoma by showing unique features different from healthy nails or nail fungus.